Intellectual Product – Page 17

Incyte’s $750M Acquisition Hits Roadblock: Key Trial Paused and Asset Cull Announced

6 months ago talkbio0Tagged asset, cull, Drug Industry, Incyte, News [Publication Type]

Incyte, $750M buyout, paused trial, asset cull, biotech news, pharmaceutical industry

Regenxbio Advances Duchenne Muscular Dystrophy Gene Therapy to Pivotal Studies, Potentially Challenging Sarepta’s Dominance

6 months ago talkbio0Tagged Approved, Biologics License Application, DMD, Duchenne, ELEVIDYS, gene therapy, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Regenxbio, SLC6A8 Inhibitor RGX-202, United States Food and Drug Administration

Regenxbio, Sarepta Therapeutics, Duchenne Muscular Dystrophy (DMD), Gene Therapy, RGX-202, Elevidys, Pivotal Studies, Biologics License Application (BLA), FDA Approval

Cybin’s Psychedelic Breakthroughs: Advancing Mental Health Treatments

6 months ago talkbio0Tagged Breakthrough Therapy, Clinical Trials, Cybin, Hallucinogens, Identifier, mental health, N,N-Dimethyltryptamine, Psilocybin, United States Food and Drug Administration

Cybin, psychedelic therapeutics, mental health treatments, deuterated psilocybin, deuterated DMT, clinical trials, FDA Breakthrough Therapy Designation.

RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry

6 months ago talkbio0Tagged Administration occupational activities, Biopharma, CHARGE Syndrome, Health Policy, Industry, nomination, RFK Jr., Skepticism, Transplant Registry Unified Management Program, Vaccines

RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration

Dupixent (Dupilumab) Advances Towards FDA Approval for Chronic Spontaneous Urticaria (CSU) in 2025

6 months ago talkbio0Tagged Biologic Medicine, Chronic Spontaneous Urticaria, dupilumab, Dupixent, Inflammation, Regeneron, Review [Publication Type], sanofi, United States Food and Drug Administration

Dupixent, Dupilumab, Chronic Spontaneous Urticaria (CSU), FDA Review, Sanofi, Regeneron, Biologic Medicine, Type 2 Inflammation, H1 Antihistamines

Bluebird Bio Confronts Financial Crunch Amidst Breakeven Projections

6 months ago talkbio0Tagged Cash, cash flow, Family Turdidae (organism), financial stability, gene therapy

Bluebird Bio, cash gap, breakeven point, financial stability, gene therapy, cash flow

Eisai Slashes Leqembi Sales Forecast Amid Continued Launch Challenges

6 months ago talkbio0Tagged Alzheimer 's disease, Biogen, Drug Industry, Eisai, Leqembi, Projections and Predictions, Sales - occupational activity

Eisai, Leqembi, Alzheimer’s disease, sales forecast, revenue expectations, Biogen, pharmaceutical industry

Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A

6 months ago talkbio0Tagged Biopharma, Health care facility, Jr., M&A, Robert F. Kennedy Jr., Transplant Registry Unified Management Program, United States Food and Drug Administration

Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.

Empowering Undergraduates: Johns Hopkins BME Design Team Transforms Healthcare Solutions

6 months ago talkbio0Tagged biomedical engineering field, Clinical Challenges, Design, Entrepreneurship, healthcare innovation, Intellectual Property, Principles, projects, regulatory frameworks, Team, Team-Based, Undergraduate Design

Biomedical Engineering, Undergraduate Design Team, Healthcare Innovation, Clinical Challenges, Design Principles, Team-Based Projects, Entrepreneurship, Intellectual Property, Regulatory Frameworks

Catalent Falls Short of Q1 Revenue Projections Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition

6 months ago talkbio0Tagged Acquisition, Catalent, Contract agreement, Drug Industry, Holdings

Catalent, Q1 Revenue, Novo Holdings, Acquisition, Pharmaceutical Industry, Contract Manufacturing